2.07  -0.19 (-8.41%)		03-02 16:00
Open: 2.165 High: 2.2 Volume: 564,821		Pre. Close: 2.26 Low: 2.05 Market Cap: 77(M)

Short term
Mid term
Targets	6-month :	3.05	1-year :	3.72
Resists	First :	2.61	Second :	3.19
Pivot price	2.07
Supports	First :	1.69	Second :	1.4
MAs	MA(5) :	2.25	MA(20) :	2.05
	MA(100) :	1.58	MA(250) :	1.65
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	62.4	D(3) :	71.9
RSI	RSI(14): 49.8
52-week	High :	3.19	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MAIA ] has closed above bottom band by 49.2%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.2 - 2.21	2.21 - 2.22
Low:	2.02 - 2.03	2.03 - 2.05
Close:	2.05 - 2.07	2.07 - 2.09

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Tue, 03 Mar 2026
MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down - Nasdaq

Mon, 02 Mar 2026
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - The Manila Times

Mon, 02 Mar 2026
Cancer immunotherapy firm MAIA raises $30M for trials, costs - Stock Titan

Mon, 02 Mar 2026
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times

Mon, 02 Mar 2026
MAIA Biotechnology (NYSE: MAIA) offers common stock and pre-funded warrants - Stock Titan

Mon, 02 Mar 2026
Cancer immunotherapy developer MAIA plans stock sale to fund trials - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.